March 2007

Silverlon® Negative Pressure Dressings Receives Product Innovation Award

Argentum Medical, LLC (Willowbrook, Ill) received the 2006 Frost & Sullivan Product Innovation Award for its Silverlon® Negative Pressure Dressings.
In more than 200 unsupported clinical cases, Silverlon dressings reduced both healing time and incidence of infection. Once placed directly on the wound surface, the filler media of choice can be placed on top of the dressing. The sustained high rate of ion release, dual flow ports for fluid management, and the durable conforming silver nylon all contribute to successful clinical results.
Siverlon dressings reduce the required number of dressing changes, which significantly reduces patient pain and labor input.
Visit http://www.silverlon.com for more information.

NPUAP Recognizes and Highlights Wound Care Achievements

The National Pressure Ulcer Advisory Panel (NPUAP) honored 2 professionals with the Kosiak and Stewart awards during its biennial consensus conference.  
Elizabeth Ayello, PhD, RN, who served as President of NPUAP in 1999, received the Koziak award. The older of the 2 NPUAP awards, it is presented to honor individuals who have made significant contributions to the prevention and/or management of pressure ulcers through their leadership in the areas of research, education, and patient care.
Courtney Lyder, a professor with the College of Nursing with the Medical College of Virginia, received the Thomas Stewart Founder’s award. This award was created to honor individuals who have made significant contributions in the area of pressure ulcer prevention and treatment — specifically in the areas of public policy.
Visit http://www.npuap.org or call 202-521-6789 for more information.

Winner Medical Group Signs 5-Year Wound Dressing Contract

Winner Medical Group, Inc. (Shenzhen City, China), signed a 5-year contract with a global medical technology company to produce its nonadherent wound dressings.
Technology driven products, such as these new nonadherent wound dressing products, mark the first order from this global medical technology products distributor. The customer plans to rebrand these products as its own and distribute them in the United States, United Kingdom, Australia, and Japan.
Since this contract is from a leading medical technology products company the ability to develop new OEM relationships and the expansion of product accessibility is a definite. Winner Medical will be able to create and capitalize on more business opportunities in the future while mass production of the initial order is expected to commence in March 2007.
Visit http://www.winnermedical.com for more information.

Lacosamide Provides Positive Results in aiding Diabetic Neuropathic Pain

Schwarz Pharma (Monheim, Germany) announces that a phase III trial implementing lacosamide for the treatment of diabetic neuropathy showed statistically significant superiority compared to placebo in the primary variable.
Patients (106) with painful diabetic neuropathy were treated in this multicenter, double blind, placebo-controlled phase III study. With such promising results underlining efficacy and safety of lacosamide in neuropathic pain, the organization is preparing the application of documents for regulatory submission.
Schwarz Pharma has identified the novel dual mode of action for lacosamide—the selective enhancement of sodium channel slow inactivation and the modulation of CRMP-2 (collapsing response mediator protein 2). Preclinical trials showed that these novel modes of action could be the basis for the efficacy of lacosamide in the treatment of epilepsy and diabetic neuropathic pain. The mechanism might also interfere with the progression of the diseases.
Visit http://www.schwarzpharma.com for more information.

Back to top
iuwerksdfgh